NCT00536003

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jul 1, 2006
Primary completion: Dec 1, 2012
Completion date: Dec 1, 2012
First posted: —
Last posted: —
Enrollment: 384
Arms / groups: 2 / —
Source: AACT · pre-existing

Sponsors

University of GenevaLead sponsor
University of GenevaOverall official - principal investigator
University of GenevaSponsor investigator
University of ZurichCollaborator
Luzerner KantonsspitalCollaborator
Hospital Italiano de Buenos AiresCollaborator
Hospital Provincial Magdalena V. de MartínezCollaborator
University of BernCollaborator
University of BaselCollaborator
Kantonsspital GraubündenCollaborator
Hospital Bernardino Rivadavia Buenos AiresCollaborator
Hospital Carlos G. Durand Buenos AiresCollaborator
CEMIC Buenos AiresCollaborator
Hospital Donación Francisco SantojanniCollaborator
Hospital Dr. Cosme Argerich Buenos AiresCollaborator
Hospital Dr. T. Alvarez Buenos AiresCollaborator
Hospital J. M. Penna Buenos AiresCollaborator
Hospital Interzonal Alberto Antranik Eurnekian, provincia Buenos AiresCollaborator
Hospital Mariano y Luciano de la Vega, provincia Buenos AiresCollaborator
Hospital J. B. Iturraspe, Santa FeCollaborator
Hospital Villa Dolores, CórdobaCollaborator
University of Buenos AiresCollaborator
Pontifical Catholic University of ArgentinaCollaborator
Universidad de MorónCollaborator
Besins HealthcareCollaborator
University of LausanneCollaborator
Cantonal Hospital of St. GallenCollaborator
Cantonal Hospital WinterthurCollaborator

Drugs studied

progesterone

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.